Idiopathic Pulmonary Fibrosis – Unmet Need – Detailed, Expanded Analysis (US/EU)

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder associated with progressive inflammation and/or fibrosis of the lung tissue. The leading cause of the disorder is unknown. IPF patients experience dyspnea and lung complications that eventually cause respiratory failure. Boehringer Ingelheim’s Ofev (nintedanib) and pirfenidone are welcome options in the treatment armamentarium for IPF, but therapies that can further delay or reverse the disease’s progression, preserve lung function, and prolong survival are greatly needed. The IPF pipeline is diverse and includes PDE4B inhibitor and prostacyclin vasodilators. In this report, we assess the clinical and commercial opportunities remaining in the IPF space through a comprehensive analysis of surveyed pulmonologists’ treatment drivers and goals and their perception of the performance of key current therapies against these goals.

Questions answered

  • What are the key treatment drivers and goals in IPF?
  • Which drug attributes are key influences, which have limited impact, and which are hidden opportunities?
  • How do current therapies such as Esbriet and Ofev perform on key treatment drivers and goals for IPF?
  • What are the key opportunities for drug development in IPF? Where do surveyed pulmonologists perceive the largest gaps in the treatment of IPF?
  • What trade-offs across different clinical attributes and prices are acceptable to U.S. and European pulmonologists for a hypothetical new IPF drug?

Product description

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.

Key feature:

The Target Product Profile (TPP) Simulator tool allows for customizable market simulations based on conjoint analysis that depicts how physicians make decisions based on actual behavior rather than opinion. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.

Markets covered: France, Germany, United Kingdom, United States

Primary research: Survey of 60 U.S. and 30 European rheumatologists fielded in January 2024

Key companies: Boehringer Ingelheim, Genentech

Key drugs: Ofev, pirfenidone, prednisone

launch Related Market Assessment Reports